A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia

Clinical trial NCT04440059 · COMPLETED

Trial details

NCT number: NCT04440059
Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Waldenstrom's Macroglobulinemia Recurrent Waldenstrom's Macroglobulinemia Refractory

Start date: 2019-08-10
Primary completion: 2024-01-09
Enrollment: 47

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.